Targeting inflammation in the preterm infant: The role of the omega-3 fatty acid docosahexaenoic acid  by Fink, Naomi H. et al.
lable at ScienceDirect
Journal of Nutrition & Intermediary Metabolism 5 (2016) 55e60Contents lists avaiJournal of Nutrition & Intermediary Metabolism
journal homepage: ht tp: / /www.jnimonline.com/Targeting inﬂammation in the preterm infant: The role of the omega-3
fatty acid docosahexaenoic acid
Naomi H. Fink a, c, Carmel T. Collins a, c, Robert A. Gibson b, Maria Makrides a, c, *,
Irmeli A. Penttila a, c
a School of Medicine, The University of Adelaide, Adelaide, SA, 5005, Australia
b School of Agriculture, Food and Wine, The University of Adelaide, Adelaide, SA, 5005, Australia
c Child Nutrition Research Centre, South Australian Health and Medical Research Institute, 72 King William Rd, North Adelaide, SA, 5006, Australiaa r t i c l e i n f o
Article history:
Received 4 December 2015
Received in revised form
20 March 2016
Accepted 22 March 2016
Available online 21 April 2016
Keywords:




Immunoregulation* Corresponding author. Child Nutrition Research Ce
and Medical Research Institute, 72 King William Rd
Australia.
E-mail address: maria.makrides@sahmri.com (M.
http://dx.doi.org/10.1016/j.jnim.2016.03.004
2352-3859/© 2016 The Authors. Published by Elseviera b s t r a c t
Long-chain polyunsaturated fatty acids are critical for the normal growth and development of preterm
infants. Interest in these compounds rests in their anti-inﬂammatory properties. Clinical conditions with
an inﬂammatory component such as bronchopulmonary dysplasia, necrotising enterocolitis and sepsis
are risks to the survival of these infants. Dysregulation of inﬂammatory responses plays a central role in
the aetiology of many of these neonatal disorders. There is evidence to suggest that the omega-3 long
chain polyunsaturated fatty acid docosahexaenoic acid (DHA) can down-regulate local and systemic
inﬂammation in adults and animal models; however, very little is known about its protective effects in
infants, especially preterm infants. Due to their immunological immaturity, preterm infants are partic-
ularly sensitive to diseases with an inﬂammatory aetiology in the early postnatal period. This makes DHA
supplementation immediately after birth to combat neonatal inﬂammation an attractive therapy.
Mechanistic data for DHA use in preterm infants are lacking and results from adult and animal studies
may not be relevant to this population because of fundamental immune system differences. While there
is increasing evidence from randomised controlled trials to support a beneﬁcial effect of DHA for the
preterm infant, more evidence is required to establish short and long-term effects of DHA on the immune
status of preterm infants.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Preterm birth, deﬁned as birth at less than 37 completed weeks
gestation, occurs in around 12% of deliveries worldwide with major
implications for the long term health of the child [1,2]. Mortality
rates of preterm infants have decreased substantially over the last
few decades due to advancements in medical care [1]. However,
morbidity rates, particularly in the very preterm infant (born less
than 28 weeks gestation) have continued to rise [1]. Functionally
and immunologically immature, the very preterm infant requires
intensive support, and the medical interventions necessary for
their survival can trigger a local or systemic inﬂammatory response
[3].ntre, South Australian Health
, North Adelaide, SA, 5006,
Makrides).
Inc. This is an open access article uPreterm infants have an under-developed immunoregulatory
system, therefore there is the potential for chronic inﬂammation to
develop [4]. Dysregulation of inﬂammatory responses plays a
central role in the aetiology of many life-threatening neonatal
disorders including bronchopulmonary dysplasia (BPD), necrotis-
ing enterocolitis (NEC) and sepsis [3e7] and presents a continuing
challenge to clinicians involved in their care. Interest is intensifying
in dietary compounds that promote resolution of inﬂammation and
confer a protective effect against development of neonatal in-
ﬂammatory disorders [8]. There is some controversy as to whether
or not preterm infants can synthesise sufﬁcient long-chain poly-
unsaturated fatty acids (LCPUFA) such as docosahexaenoic acid
(DHA) and arachidonic acid (AA) from essential fatty acid (EFA)
precursors [9e13] because genetic variants in the fatty acid desa-
turase genes may affect rates of synthesis of LCPUFA [13,14].
However, all infants receive an exogenous source of EFA and/or
LCPUFA, via breast milk, lipid emulsions, formula or a combination
of these sources [15]. Interest in DHA supplementation and itsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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these sources do not provide sufﬁcient levels of DHA for these in-
fants [16]. This reviewwill focus speciﬁcally on the potential for the
omega-3 LCPUFA DHA to act as an immunoregulatory agent to
improve clinical outcomes in preterm infants.
2. Omega-3 LCPUFA and their role in early immune
development
Preterm infants have a fundamentally different immune system
to that of an adult or even a term infant, making them especially
susceptible to an exaggerated immune activation [3]. The preterm
infant relies heavily on the non-speciﬁc innate immune response
for defence [3,17]. The antigen-speciﬁc adaptive immune system of
preterm infants is also underdeveloped at birth, particularly with
regard to T cells mediating inﬂammatory responses (T helper 1:
Th1) and the important T cells involved in regulating the immune
response (T-regulatory: T-reg) [3,18e20]. Ineffective T-reg function
after birth, when the infant is exposed to a massive environmental
antigenic onslaught from the birth process and neonatal intensive
care unit (NICU), can result in excess inﬂammation and a lowered
ability to down-regulate immune responses once initiated.
Breast milk has long been considered the gold standard for in-
fant nutrition and is essential for promoting appropriate immune
development in newborns [21]. In addition to a full complement of
LCPUFA, breast milk also contains a complex mixture of immuno-
logically active components such as growth factors, lactoferrin,
prostaglandins, immunoglobulins, cytokines and immune cells
[22,23]. Together with LCPUFA, the immunoregulatory bioactives in
breast milk such as interleukin (IL) 10, transforming growth factor
(TGF) b and DHA serve as mediators to promote oral tolerance and
they also modulate developing immune responses while the infant
develops their own immunoregulatory ability [3,19,20,24e28]. This
immune maturation is crucial in order for a complex and dynamic
relationship to develop between the innate and adaptive immune
system [4,18,19,29], allowing infants to respond effectively and
appropriately to self and pathogenic environmental stimuli [25,30].
Without appropriate regulation, an unchecked inﬂammatory
pathophysiology can result, leading to many neonatal morbidities
[3,4,17].
3. Inﬂammatory disorders in the neonate and the role of DHA
A heightened immune response leading to an exaggerated
release of inﬂammatory mediators is a hallmark of BPD and other
inﬂammatory disorders in the neonatal period, such as sepsis, NEC
and retinopathy of prematurity (ROP) [3]. These disorders have a
multi-factorial pathogenesis for which a single medication or
comprehensive treatment is not available. Data from both preterm
infant [4,31] and animal studies [32,33] support the potential for
DHA to serve as a general preventative agent against inﬂammation
without inhibiting development or function of underdeveloped
organs.
3.1. Bronchopulmonary dysplasia
BPD is a disorder of prematurity characterised by the need for
assisted ventilation or supplemental oxygen at 36 weeks post-
menstrual age and signs of impaired alveolarisation and vasculo-
genesis in the lungs [4,34]. BPD occurs in approximately 45% of
infants born less than 29 weeks gestation that survive preterm
birth [4,35]. Ongoing lung damage may be caused by the preterm
infant's inability to down-regulate and maintain control of the in-
ﬂammatory immune response, leading to a chronic inﬂammatory
state [35e38]. Decreased levels of DHA have been found to beassociated with respiratory disease in preterm infants [39,40] and
results from a prospective observational study in preterm infants
supports this trend [41]. The best evidence for the ability of DHA to
improve respiratory outcomes in preterm infants comes from our
“Docosahexaenoic acid for Improvement in Neurodevelopmental
Outcomes (DINO) trial”. In the subgroup of infants born weighing
less than 1250 g, those who received higher-DHA breast milk or
formula had a reduced rate of BPD [42]. A recent meta-analysis
supports the potential for DHA as a preventative agent against
adverse respiratory outcomes when administered early in life [4].
These data support the concept that there is an early window of
opportunity for effective immunomodulationwith DHA; the critical
period is when the immune system is still developing and before
clinical phenotypes have been established in the infant [8,43].
3.2. Necrotising enterocolitis
NEC is predominantly a disease of prematurity, it is the most
common gastrointestinal illness in newborns and has a high mor-
tality rate [44e46]. As the disease progresses, inﬂammation in the
intestineworsens causing breakdown of themucosal barrier and an
escalating immune cascade leading to sepsis, shock and even death
[6,44,47]. The risk for developing NEC is strongly inﬂuenced by
commensal bacteria, which exert metabolic, nutritional and
immunological effects on the host [48]. A preterm infant has very
low bacterial diversity and the establishment of a more complex
microbiome is easily disrupted by events related to premature
birth, for example, early antibiotic administration and Caesarean
sections [49e51]. This process, termed dysbiosis, is implicated in
the development of both sepsis and NEC [48].
Breast milk is the ﬁrst choice for nutrition in the preterm infant
and its early introduction is critical due to known gastrointestinal
beneﬁts [52]. Breastmilk promotes bacterial colonisation of the gut,
which in turn, is a major promoter of the development of immu-
noregulatory pathways required to mediate inﬂammation and
bring about immunological homoeostasis [53]. Enteral feeding
regimens for preterm infants consist of breast milk, preterm for-
mula, or more commonly in the ﬁrst few weeks, a combination of
the two [52]. Both are sources of DHA which has been shown to
inﬂuence the composition of the microbiome, albeit with contro-
versial efﬁcacy [32,54e56]. It has been proposed that fat intake and
type of fat (saturated vs. unsaturated) inﬂuences the distribution of
beneﬁcial and protective bacteria in preterm infants [51]. A meta-
analyse of trials in which NEC was reported has shown no beneﬁt
for omega-3 LCPUFA [4]; however none of the included trials were
speciﬁcally designed nor powered to determine the true effect of
DHA on NEC. Data from neonatal animal models is promising, as it
has been reported that omega-3 LCPUFA-enriched diets support the
colonisation of beneﬁcial bacteria and protect against growth of
pathogenic bacteria [32] and are protective against NEC [57].
Further, large-scale studies are required to ﬁrst determine if DHA
can reduce the incidence of NEC, and secondly if it is through a
direct anti-inﬂammatory action or if DHA inﬂuences microbial
communities directly in the gut.
3.3. Sepsis
Sepsis is a systemic inﬂammation caused by infection. Globally,
sepsis is responsible for approximately 15% of neonatal deaths [58],
with rates of infection dependent on the geographic region
[5,59,60]. In preterm infants, sepsis is classiﬁed as either early-
onset (<72 h of life) or late-onset (>72 h of life), with the latter
being a common complication associated with prolonged admis-
sion to NICU [59,60]. The distinction between the two is of clinical
importance, as early-onset sepsis usually results from exposure to
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from bacteria in the environment (ie. nosocomial infections) [59].
Different microorganisms are responsible for the pathogenesis of
sepsis; bacterial infections are most common, but fungal, viral and
parasitic infections are possible as well [59]. Decreased DHA has
been associated with an increased risk of late-onset sepsis in pre-
term infants [39]. An appropriate balance of omega-3/6 LCPUFA has
an impact on disease risk and alterations in these LCPUFA could be
responsible for immune dysregulation and subsequent increase in
sepsis risk [39].
3.4. Retinopathy of prematurity
ROP is the second leading cause of childhood blindness world-
wide [61,62]. Impaired vasculogenesis and improper retinal
neuronal development are responsible for the pathogenesis of ROP
[63]. Because DHA is an integral part of cell membrane phospho-
lipids, it may protect against the processes that impair vascular
formation in ROP and thus may help to ameliorate vascular ab-
normalities and disease development [64e67]. Although a recent
meta-analysis has shown no clear trend in risk for ROP between
groups supplemented with omega-3 LCPUFA [4], a single study has
reported that omega-3 LCPUFA supplementation was associated
with a reduction in the incidence of ROP in preterm infants [65].
Results from clinical studies in preterm infants and animal
studies supports the need for further large-scale randomised-
controlled trials to determine the clinical efﬁcacy of DHA supple-
mentation to prevent inﬂammatory conditions in preterm infants.
4. Potential mechanisms for Omega-3 LCPUFA in the
regulation of inﬂammation
The growing body of evidence suggests that dietary intake of
LCPUFA early in life could inﬂuence immune development and
other health outcomes. While there is extensive literature on the
mechanisms of action of DHA and inﬂammation in adult disease,
the targets that DHA acts on to exert its inﬂuence during initial
immune development and resulting clinical conditions remains
unclear. Studies in adults and animal models show that DHA in-
ﬂuences a wide variety of mechanisms; some of which may be
relevant to the neonate. These mechanisms include alterations in
cell signalling pathways via changes to lipid rafts and cell mem-
brane composition [68], modiﬁcations to receptor-mediated path-
ways such as PPARg, NFkB or GPR120 to inhibit or attenuate
inﬂammation [69] [70] and increases in anti-inﬂammatory pros-
taglandin synthesis [71]. DHA may also inﬂuence the gut micro-
biome to promote immune regulation [54,56] and decrease
oxidative stress [72]. However, there is a large gap in the literature
relating to which aspects of inﬂammation are responsive to DHA in
a neonate, or more speciﬁcally, in a preterm infant [73]. Preterm
infants are an immunologically unique population and therefore
mechanistic data pertaining to DHA's action in adults may not
appropriate to predict efﬁcacy in this population. In the following
sections we review the evidence for the immunoregulatory efﬁcacy
of DHA, the effect of downstream metabolites of omega-3 LCPUFA
and oxidative stress in preterm infants and pretermmodels (in vitro
and animal studies). Important trends in data from studies utilising
LCPUFA supplementation in term infants is also included when
relevant or when data in preterm infants are unavailable.
4.1. DHA and the immune response: cytokine synthesis and release
In preterm infants, LCPUFA supplementation has been reported
to modulate cytokine synthesis and immune cell phenotypes [74].
In a double-blind, randomised-controlled clinical trial in preterminfants, a medium-chain triglyceride/omega-3 LCPUFA emulsion
was found to attenuate the inﬂammatory response compared to a
soy (omega-6) emulsion [75]. Pro-inﬂammatory cytokines (IL-6 and
IL-8) were signiﬁcantly reduced at study-end in the omega-3
LCPUFA group [75], highlighting the potential for omega-3
LCPUFA to dampen the heightened immune response seen in pre-
term infants after birth. The addition of DHA and AA (omega-6
LCPUFA) to standard infant formula has been shown to increase the
production of immunoregulatory IL-10, reduce IL-2 and increase
the proportion of antigen-mature memory (CD45ROþ) CD4þ cells
(important in adaptive immunity) in infants to levels comparable to
those seen in the breast milk-fed group [74], indicating an effect of
DHA on immune maturation [74]. Furthermore, Gold et al. (2006)
observed that omega-3 eicosapentaenoic acid (EPA) and AA
reduced antigen- and mitogen-stimulated IFNg production in vitro
in cord blood samples from a US birth cohort study (30e42 weeks
gestation) [76]. These data support the potential for omega-3
LCPUFA to inhibit release of pro-inﬂammatory cytokines by Th1
cells. Additionally, lymphocyte proliferation was reduced by EPA
and AA, indicating an attenuation of the immune response by both
omega-3 and 6 LCPUFA [76].
While immune response data from preterm infants are limited,
data from term infants are supportive of an immunoregulatory role
for DHA. Cellular immune responses were compared in term neo-
nates who received either standard formula, formula supple-
mented with DHA/AA or breast milk from 2 to 6 weeks of life [77].
Although results were not signiﬁcantly different, the infants that
received the formula supplemented with DHA/AA had similar
cytokine and T cell responses to those in the breast milk group [77].
Cultured lymphocytes from both formula groups produced more
pro-inﬂammatory cytokines than the human milk fed group.
However at 6 weeks, an increased pro-inﬂammatory TNFa
response was seen in the formula group but not for the
formula þ DHA/AA group [77]. In addition, the group without
LCPUFA supplementation exhibited less maturation of the adaptive
immune response (fewer CD4þCD28 þ cells) and they had signif-
icantly fewer peripheral blood effector memory T cells
(CD3þCD44þ cells), which suggests that these fatty acids inﬂuence
the degree of T cell maturation and development of effector
memory T cells [77] [78]. A decrease in pro-inﬂammatory cytokines
in response to in vitro stimulation by allergens (ovalbumin, house
dust mite, cat hair, phytohaemagglutinin) was also reported for
immune cells from term infants, whose mothers were supple-
mentedwith ﬁsh oil (3.7 g/day omega-3 LCPUFA) during pregnancy
[79]. The data supports a role for early dietary LCPUFA in immune
development and regulation.
Animal studies also reinforce the anti-inﬂammatory role of
omega-3 LCPUFA seen in preterm and term infants. A reduction in
systemic inﬂammation would be reﬂected by a reduction in pro-
inﬂammatory mediators and/or the increase in regulatory cyto-
kines. In a neonatal piglet model, increased dietary DHA and
decreased omega-6 LCPUFA was associated with a reduction in
systemic inﬂammation (as measured by C-reactive protein (CRP))
[33]. Mice receiving an omega-3 LCPUFA supplemented diet pro-
duced offspring with signiﬁcantly increased immunoregulatory IL-
10 levels in the colon and spleen [54]. Importantly, variations in the
local tissue cytokine milieu also have the potential to inﬂuence
other immune cells, such as antigen presenting cells (APC) that are
critical for initiating immune responses [80]. DHA-induced changes
in the cytokine environment may have downstream effects on
priming of APC and other immune cells for the promotion of an
anti-inﬂammatory response during initial antigen encounter [8,80].
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Downstream metabolites of LCPUFA, such as resolvins and
protectins, are also important in mediating an anti-inﬂammatory
response. Resolvins are directly synthesised metabolites of
omega-3 LCPUFA and play a key role in terminating inﬂammatory
responses [81]. These metabolites promote resolution and tissue
repair and importantly for the preterm infant this occurs without
compromising host defence [81]. Much of the work that examines
the interaction between LCPUFA, resolvins and inﬂammation has
been conducted in vitro in samples obtained from adult and animal
models, leaving a large gap in knowledge for the effectiveness in
neonates. Results from neonatal animal models serve as the best
indicator for effectiveness of LCPUFA's ability to trigger resolution
of inﬂammation. Martin et al. (2014) recently examined the effect of
supplementation with a downstream metabolite of DHA, Resolvin
D1 (RvD1), along with a downstream metabolite of AA, lipoxin A4
(LxA4), in a neonatal mouse model of BPD [82]. The results
demonstrate that these metabolites reversed the histologic and
biochemical changes associated with lung injury in the mouse
model. Whilst RvD1 and LxA4 were shown to reduce alveolar
damage when administered on their own, the most signiﬁcant
reduction in alveolar damage was seen when the two were com-
bined [82]. Similarly, Velten et al. (2014) also reported that prenatal
DHA supplementation reduced neonatal lung inﬂammation in a
mouse model [83]. These recent ﬁndings suggest biological plau-
sibility for a mechanistic role of terminal metabolites of DHA in
combatting inﬂammatory lung damage.
4.3. DHA and the mediation of oxidative stress
Supplemental oxygen therapy, while vital to the survival of in-
fants with BPD, also places a large oxidative stress burden on the
infant [7]. Furthermore, if the infant is also receiving parenteral
nutrition, the lipids are subjected to an increased risk for peroxi-
dation while exposed to supplemental oxygen. DHA and its
downstream metabolites have been reported to reduce oxidative
stress [84]. A double-blind randomised controlled trial in preterm
infants (n ¼ 38) reports that a parenteral lipid emulsion containing
omega-3 LCPUFA reduced oxidative stress compared to standard
lipids (soy) [85]. Oxidative stress levels were determined by
Vitamin A, E and total antioxidant potential. Positive results with
respect to omega-3 LCPUFA and oxidative stress were also obtained
when very preterm infants (n ¼ 30) were randomised to either a
lipid emulsion containing soy and olive oils (ClinOleic®) or one
containing soy, medium-chain triglycerides, olive oil and ﬁsh oil
(SMOFlipid®) [86]. Vitamin E levels and plasma F2-isoprostanes
(lipid peroxidation marker) were used to quantify levels of oxida-
tive stress in the infants. Compared to ClinOleic®, SMOFlipid®
reduced oxidative stress in this high risk infant population and was
determined to be safe and well-tolerated [86].
Results from research conducted in children and adolescents
with acute lymphoblastic lymphoma (ALL) are relevant as they add
strength to the use of DHA as an adjuvant therapy to combat
oxidative stress in preterm infants. In a randomised, double-blind,
placebo-controlled trial, participants (n ¼ 70) received either
1000 mg/day ﬁsh or placebo oil in combination with their metho-
trexate regimen [87]. Methotrexate is a necessary treatment in
patients with ALL but is known to induce hepatotoxicity, the
pathogenicity of which is mainly due to oxidative stress [87].
Omega-3 LCPUFA as an adjunct therapy in these patients amelio-
rated the hepatotoxicity compared to placebo and no adverse re-
actions to the ﬁsh oil were observed [87]. These results are
promising; however, more in-depth studies are required in larger
cohorts to establish the robustness of these ﬁndings and themechanisms underlying the action of DHA against oxidative stress.
In a neonatal guinea pig model indicators of oxidative stress
(peroxide and aldehyde concentrations) were reduced when
guinea pigs were fed an omega-3 LCPUFA emulsion compared to an
omega-6 LCPUFA emulsion [88]. Levels of pro-inﬂammatory IL-1
and tumour necrosis factor alpha (TNFa) mRNA were also signiﬁ-
cantly reduced in the ﬁsh oil emulsion group [88]. Further research
in humans to determine appropriate dose and timing regimens is
required to reveal whether DHAwould serve as an effective adjunct
therapy to combat oxidative stress in infants the NICU.
5. Implications and conclusions
There is increasing experimental evidence and a convincing
rationale for DHA supplementation to improve clinical outcome in
preterm infants by targeting the critical window of time where
immunomodulation has the greatest potential for beneﬁt [4,89].
However, several areas require further consideration and research.
First, further large-scale interventions are required in order to
determine the clinical efﬁcacy of DHA during the neonatal period in
this unique and vulnerable population. Second, to optimise DHA's
beneﬁt on clinical outcomes, it is essential that the sites of action of
both the fatty acid and its downstream mediators on the preterm
infant's immune system are thoroughly elucidated. This knowledge
would allow clinicians to determine whether DHA would be best
used as a preventative versus treatment option in preterm infants.
Lastly, the mechanisms of action of DHA on the immune system in
the short and long-term must be examined.
It is anticipated that the results from a large-scale randomised
clinical trial of enteral DHA supplementation on respiratory out-
comes and other parameters in preterm infants that is currently
underway in Australia, New Zealand and Singapore will answer
some of these questions and guide future research and recom-
mendations. The N3RO trial (n-3 LCPUFA for the improvement in
Respiratory Outcomes- ACTRN trial #12612000503820) will shed
light on the mechanisms of action of omega-3 LCPUFA on the im-
mune system while it is still functionally immature.
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